

**Clinical trial results:****A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted with Ritonavir (RTV) Liquid with an Optimized NRTI Background Therapy, in HIV Infected Pediatric Patients Greater Than or Equal to 3 Months to Less Than 6 Years. (Pediatric Atazanavir International Clinical Evaluation: the PRINCE I study)****Summary**

EudraCT number	2009-016361-28
Trial protocol	PL IT Outside EU/EEA
Global end of trial date	11 September 2017

**Results information**

Result version number	v1 (current)
This version publication date	25 March 2018
First version publication date	25 March 2018

**Trial information****Trial identification**

Sponsor protocol code	AI424-397
-----------------------	-----------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01099579
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	Bristol-Myers Squibb
Sponsor organisation address	Chaussée de la Hulpe 185, Brussels, Belgium, 1170
Public contact	EU Study Start-Up Unit, Bristol-Myers Squibb International Corporation, clinical.trials@bms.com
Scientific contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, Clinical.Trials@bms.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000804-PIP01-09
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

### Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 September 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	11 September 2017
Was the trial ended prematurely?	No

Notes:

### General information about the trial

Main objective of the trial:

The primary objective of Study AI424397 was to describe the safety of ATV powder formulation boosted with RTV liquid-based highly active antiretroviral therapy regimens in pediatric subjects dosed through 48 weeks (or a minimum of 24 weeks for subjects who were 5.5 years of age at the time of study start)

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 November 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

### Population of trial subjects

#### Subjects enrolled per country

Country: Number of subjects enrolled	Brazil: 1
Country: Number of subjects enrolled	Chile: 7
Country: Number of subjects enrolled	Mexico: 13
Country: Number of subjects enrolled	Peru: 3
Country: Number of subjects enrolled	South Africa: 56
Country: Number of subjects enrolled	Thailand: 2
Worldwide total number of subjects	82
EEA total number of subjects	0

Notes:

#### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	41
Children (2-11 years)	41
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 82 pediatric subjects were enrolled, and 56 received treatment. Reasons for not receiving treatment treated were: no longer met study criteria (23 subjects), other reason (2 subjects), and withdrew consent (1 subjects).

### Period 1

Period 1 title	Stage 1 (ATV powder formulation)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg

Arm description:

Subjects weighing 5 to <10 kg received atazanavir (ATV), 150-mg powder dosed in 50-mg sachet packets, and ritonavir (RTV) oral solution, 80 mg. Stage 1: Initial dose was determined by subject's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). If water was used, mixture must have been taken with food. The entire contents of the mixture must have been consumed to obtain the full dose. The ritonavir oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Subjects who reached the age of 6 years or a weight of 25 kg were transitioned to the capsule formulation of ATV. Those who weighed 15 to <20 kg received ATV, 150 mg, with RTV, 100 mg; those who weighed 20 to <40 mg received ATV, 200, with RTV, 100 mg; and those who weighed at least 40 mg received ATV, 300 mg, with RTV, 100 mg.

Arm type	Experimental
Investigational medicinal product name	Atazanavir
Investigational medicinal product code	
Other name	Reyataz BMS-232632
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Powder, oral, dosed by weight. Subjects who weighed 5 to &lt;10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg once per day for 48 weeks or until pediatric indication is locally approved and subject meets requirements to receive appropriate formulation

Investigational medicinal product name	Ritonavir
Investigational medicinal product code	
Other name	Norvir
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and subject meets requirements to receive appropriate formulation

<b>Arm title</b>	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg
------------------	----------------------------------------------------------

Arm description:

Subjects weighing 10 to <15 kg received ATV powder, 200 mg, dosed in 50-mg sachet packets and RTV oral solution, 80 mg. Stage 1: Initial dose was determined by the subject's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). If water was used, mixture must have been taken with food. All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage

2: Subjects who reached the age of 6 years or a weight 25 kg were transitioned to the capsule formulation of ATV. Those who weighed 15 to <20 kg received ATV, 150 mg, with RTV, 100 mg; those who weighed 20 to <40 mg received ATV, 200, with RTV, 100 mg; and those who weighed at least 40 mg received ATV, 300 mg, with RTV, 100 mg.

Arm type	Experimental
Investigational medicinal product name	Ritonavir
Investigational medicinal product code	
Other name	Norvir
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and subject meets requirements to receive appropriate formulation

Investigational medicinal product name	Atazanavir
Investigational medicinal product code	
Other name	Reyataz BMS-232632
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Powder, oral, dosed by weight. Subjects who weighed 5 to <10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to <15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to <25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and subject meets requirements to receive appropriate formulation

<b>Arm title</b>	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg
------------------	----------------------------------------------------------

Arm description:

Subjects weighing 15 to <25 kg received 250 mg of ATV powder dosed in 50-mg sachet packets, with 80 mg of RTV solution. Stage 1: Initial dose was determined by the subject's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). If water was used, mixture must have been taken with food. The entire contents of the mixture must have been consumed to obtain the full dose. The ritonavir oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Subjects who reached the age of 6 years or a weight 25 kg were transitioned to the capsule formulation of ATV. Those who weighed 15 to <20 kg received ATV, 150 mg, with RTV, 100 mg; those who weighed 20 to <40 mg received ATV, 200, with RTV, 100 mg; and those who weighed at least 40 mg received ATV, 300 mg, with RTV, 100 mg.

Arm type	Experimental
Investigational medicinal product name	Ritonavir
Investigational medicinal product code	
Other name	Norvir
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and subject meets requirements to receive appropriate formulation

Investigational medicinal product name	Atazanavir
Investigational medicinal product code	
Other name	Reyataz BMS-232632
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Powder, oral, dosed by weight. Subjects who weighed 15 to &lt;25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and subject meets requirements to receive appropriate formulation

<b>Number of subjects in period 1</b> <sup>[1]</sup>	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg
Started	21	19	16
Completed	17	14	15
Not completed	4	5	1
Consent withdrawn by subject	-	-	1
Adverse event, non-fatal	4	1	-
Poor compliance/noncompliance	-	2	-
Lack of efficacy	-	2	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: A total of 82 pediatric subjects were enrolled, and 56 received treatment. Reasons for not receiving treatment treated were: no longer met study criteria (23 subjects), other reason (2 subjects), and withdrew consent (1 subjects).

**Period 2**

Period 2 title	Stage 2 (ATV capsules )
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

**Arms**

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg

Arm description:

Subjects weighing 5 to <10 kg received atazanavir (ATV), 150-mg powder dosed in 50-mg sachet packets, and ritonavir (RTV) oral solution, 80 mg. Stage 1: Initial dose was determined by subject's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). If water was used, mixture must have been taken with food. The entire contents of the mixture must have been consumed to obtain the full dose. The ritonavir oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Subjects who reached the age of 6 years or a weight of 25 kg were transitioned to the capsule formulation of ATV. Those who weighed 15 to <20 kg received ATV, 150 mg, with RTV, 100 mg; those who weighed 20 to <40 mg received ATV, 200, with RTV, 100 mg; and those who weighed at least 40 mg received ATV, 300 mg, with RTV, 100 mg.

Arm type	Experimental
Investigational medicinal product name	Ritonavir
Investigational medicinal product code	
Other name	Norvir
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and subjects meets requirements to receive appropriate formulation

Investigational medicinal product name	Atazanavir
Investigational medicinal product code	
Other name	Reyataz BMS-232632
Pharmaceutical forms	Powder for oral solution, Capsule
Routes of administration	Oral use

Dosage and administration details:

Powder, oral, dosed by weight. Subjects who weighed 5 to &lt;10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg once per day for 48 weeks or until pediatric indication is locally

<b>Arm title</b>	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg
------------------	----------------------------------------------------------

Arm description:

Subjects weighing 10 to <15 kg received ATV powder, 200 mg, dosed in 50-mg sachet packets and RTV oral solution, 80 mg. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). If water was used, mixture must have been taken with food. All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Subjects who reached the age of 6 years or a weight 25 kg were transitioned to the capsule formulation of ATV. Those who weighed 15 to <20 kg received ATV, 150 mg, with RTV, 100 mg; those who weighed 20 to <40 mg received ATV, 200, with RTV, 100 mg; and those who weighed at least 40 mg received ATV, 300 mg, with RTV, 100 mg.

Arm type	Experimental
Investigational medicinal product name	Ritonavir
Investigational medicinal product code	
Other name	Norvir
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and subject meets requirements to receive appropriate formulation

Investigational medicinal product name	Atazanavir
Investigational medicinal product code	
Other name	Reyataz BMS-232632
Pharmaceutical forms	Powder for oral solution, Capsule
Routes of administration	Oral use

Dosage and administration details:

Powder, oral, dosed by weight. Subjects who weighed 10 to &lt;15 kg received ATV, 200 mg, and RTV, 80 mg once per day for 48 weeks or until pediatric indication is locally approved and subject meets requirements to receive appropriate formulation

<b>Arm title</b>	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg
------------------	----------------------------------------------------------

Arm description:

Subjects weighing 15 to <25 kg received 250 mg of ATV powder dosed in 50-mg sachet packets, with 80 mg of RTV solution. Stage 1: Initial dose was determined by the subject's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). If water was used, mixture must have been taken with food. The entire contents of the mixture must have been consumed to obtain the full dose. The ritonavir oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Subjects who reached the age of 6 years or a weight 25 kg were transitioned to the capsule formulation of ATV. Those who weighed 15 to <20 kg received ATV, 150 mg, with RTV, 100 mg; those who weighed 20 to <40 mg received ATV, 200, with RTV, 100 mg; and those who weighed at least 40 mg received ATV, 300 mg, with RTV, 100 mg.

Arm type	Experimental
Investigational medicinal product name	Atazanavir
Investigational medicinal product code	
Other name	Reyataz BMS-232632
Pharmaceutical forms	Powder for oral solution, Capsule
Routes of administration	Oral use

Dosage and administration details:

Powder, oral, dosed by weight. Subjects who weighed 15 to &lt;25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and subject meets requirements to receive appropriate formulation

Investigational medicinal product name	Ritonavir
Investigational medicinal product code	
Other name	Norvir
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and subject meets requirements to receive appropriate formulation

<b>Number of subjects in period 2<sup>[2]</sup></b>	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg
Started	16	14	15
Completed	10	9	9
Not completed	6	5	6
No longer met study criteria	2	2	1
Consent withdrawn by subject	1	1	1
Poor/Non-Compliance	2	-	1
Adverse event, non-fatal	-	1	-
Lost to follow-up	1	1	1
Lack of efficacy	-	-	2

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Not all subjects continued to stage 2.

## Baseline characteristics

### Reporting groups

Reporting group title	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg
-----------------------	----------------------------------------------------------

Reporting group description:

Subjects weighing 5 to <10 kg received atazanavir (ATV), 150-mg powder dosed in 50-mg sachet packets, and ritonavir (RTV) oral solution, 80 mg. Stage 1: Initial dose was determined by subject's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). If water was used, mixture must have been taken with food. The entire contents of the mixture must have been consumed to obtain the full dose. The ritonavir oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Subjects who reached the age of 6 years or a weight of 25 kg were transitioned to the capsule formulation of ATV. Those who weighed 15 to <20 kg received ATV, 150 mg, with RTV, 100 mg; those who weighed 20 to <40 mg received ATV, 200, with RTV, 100 mg; and those who weighed at least 40 mg received ATV, 300 mg, with RTV, 100 mg.

Reporting group title	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg
-----------------------	----------------------------------------------------------

Reporting group description:

Subjects weighing 10 to <15 kg received ATV powder, 200 mg, dosed in 50-mg sachet packets and RTV oral solution, 80 mg. Stage 1: Initial dose was determined by the subject's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). If water was used, mixture must have been taken with food. All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Subjects who reached the age of 6 years or a weight 25 kg were transitioned to the capsule formulation of ATV. Those who weighed 15 to <20 kg received ATV, 150 mg, with RTV, 100 mg; those who weighed 20 to <40 mg received ATV, 200, with RTV, 100 mg; and those who weighed at least 40 mg received ATV, 300 mg, with RTV, 100 mg.

Reporting group title	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg
-----------------------	----------------------------------------------------------

Reporting group description:

Subjects weighing 15 to <25 kg received 250 mg of ATV powder dosed in 50-mg sachet packets, with 80 mg of RTV solution. Stage 1: Initial dose was determined by the subject's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). If water was used, mixture must have been taken with food. The entire contents of the mixture must have been consumed to obtain the full dose. The ritonavir oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Subjects who reached the age of 6 years or a weight 25 kg were transitioned to the capsule formulation of ATV. Those who weighed 15 to <20 kg received ATV, 150 mg, with RTV, 100 mg; those who weighed 20 to <40 mg received ATV, 200, with RTV, 100 mg; and those who weighed at least 40 mg received ATV, 300 mg, with RTV, 100 mg.

Reporting group values	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg
Number of subjects	21	19	16
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	21	6	0
Children (2-11 years)	0	13	16
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0

Age Continuous Units: months arithmetic mean standard deviation	7.3 ± 4.05	35.4 ± 11.63	52.1 ± 10.49
Gender, Male/Female Units: Subjects			
Female	10	12	6
Male	11	7	10
Race/Ethnicity, Customized Units: Subjects			
Not Hispanic or Latino  Not reported	0 21	0 19	1 15
Race/Ethnicity, Customized Units: Subjects			
White  Black/African American  Asian  Other	2 13 0 6	3 12 1 3	6 7 0 3
Country Units: Subjects			
Chile  Mexico  Peru  South Africa  Thailand	1 2 1 17 0	2 3 0 13 1	3 4 1 8 0
HIV RNA Categories Units: Subjects			
<30,000 c/mL 30,000 to 100,000 c/mL >100,000 c/mL	3 0 18	2 7 10	9 3 4
CD4 Percent Categories Units: Subjects			
<15  15 to <25  >=25  Not reported	2 7 7 5	2 6 6 5	1 4 6 5
Prior Antiretroviral (ARV) Treatment Use			
ATV naive is defined as without prior exposure to ARV treatment; ARV experienced is defined as previous exposure to ARV drugs through prior treatment for HIV infection or through postnatal treatment with ≥1 ARVs for the prevention of mother-to-child-transmission in accordance with multiple international guidelines. Subjects exposed to ARVs in utero or intrapartum were permitted in the study but were considered treatment naive.			
Units: Subjects			
ARV-experienced ARV-naive	14 7	9 10	11 5
HIV RNA Units: Log10 c/mL arithmetic mean standard deviation	4.77 ± 0.602	4.83 ± 0.268	4.18 ± 0.727
CD4 Count Units: Cells/mm <sup>3</sup> arithmetic mean	1594.1	1107.4	661.1

standard deviation	± 897.19	± 643.25	± 302.60
CD4 Percent			
Units: Percentage			
arithmetic mean	25.4	22.0	27.5
standard deviation	± 12.11	± 9.35	± 9.85

<b>Reporting group values</b>	Total		
Number of subjects	56		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	27		
Children (2-11 years)	29		
Adolescents (12-17 years)	0		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age Continuous			
Units: months			
arithmetic mean			
standard deviation	-		
Gender, Male/Female			
Units: Subjects			
Female	28		
Male	28		
Race/Ethnicity, Customized			
Units: Subjects			
Not Hispanic or Latino	1		
Not reported	55		
Race/Ethnicity, Customized			
Units: Subjects			
White	11		
Black/African American	32		
Asian	1		
Other	12		
Country			
Units: Subjects			
Chile	6		
Mexico	9		
Peru	2		
South Africa	38		
Thailand	1		
HIV RNA Categories			
Units: Subjects			
<30,000 c/mL	14		
30,000 to 100,000 c/mL	10		
>100,000 c/mL	32		
CD4 Percent Categories			

Units: Subjects			
<15	5		
15 to <25	17		
>=25	19		
Not reported	15		
Prior Antiretroviral (ARV) Treatment Use			
ATV naive is defined as without prior exposure to ARV treatment; ARV experienced is defined as previous exposure to ARV drugs through prior treatment for HIV infection or through postnatal treatment with ≥1 ARVs for the prevention of mother-to-child-transmission in accordance with multiple international guidelines. Subjects exposed to ARVs in utero or intrapartum were permitted in the study but were considered treatment naive.			
Units: Subjects			
ARV-experienced	34		
ARV-naive	22		
HIV RNA			
Units: Log10 c/mL			
arithmetic mean			
standard deviation	-		
CD4 Count			
Units: Cells/mm <sup>3</sup>			
arithmetic mean			
standard deviation	-		
CD4 Percent			
Units: Percentage			
arithmetic mean			
standard deviation	-		

## End points

### End points reporting groups

Reporting group title	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg
-----------------------	----------------------------------------------------------

#### Reporting group description:

Subjects weighing 5 to <10 kg received atazanavir (ATV), 150-mg powder dosed in 50-mg sachet packets, and ritonavir (RTV) oral solution, 80 mg. Stage 1: Initial dose was determined by subject's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). If water was used, mixture must have been taken with food. The entire contents of the mixture must have been consumed to obtain the full dose. The ritonavir oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Subjects who reached the age of 6 years or a weight of 25 kg were transitioned to the capsule formulation of ATV. Those who weighed 15 to <20 kg received ATV, 150 mg, with RTV, 100 mg; those who weighed 20 to <40 mg received ATV, 200, with RTV, 100 mg; and those who weighed at least 40 mg received ATV, 300 mg, with RTV, 100 mg.

Reporting group title	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg
-----------------------	----------------------------------------------------------

#### Reporting group description:

Subjects weighing 10 to <15 kg received ATV powder, 200 mg, dosed in 50-mg sachet packets and RTV oral solution, 80 mg. Stage 1: Initial dose was determined by the subject's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). If water was used, mixture must have been taken with food. All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Subjects who reached the age of 6 years or a weight 25 kg were transitioned to the capsule formulation of ATV. Those who weighed 15 to <20 kg received ATV, 150 mg, with RTV, 100 mg; those who weighed 20 to <40 mg received ATV, 200, with RTV, 100 mg; and those who weighed at least 40 mg received ATV, 300 mg, with RTV, 100 mg.

Reporting group title	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg
-----------------------	----------------------------------------------------------

#### Reporting group description:

Subjects weighing 15 to <25 kg received 250 mg of ATV powder dosed in 50-mg sachet packets, with 80 mg of RTV solution. Stage 1: Initial dose was determined by the subject's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). If water was used, mixture must have been taken with food. The entire contents of the mixture must have been consumed to obtain the full dose. The ritonavir oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Subjects who reached the age of 6 years or a weight 25 kg were transitioned to the capsule formulation of ATV. Those who weighed 15 to <20 kg received ATV, 150 mg, with RTV, 100 mg; those who weighed 20 to <40 mg received ATV, 200, with RTV, 100 mg; and those who weighed at least 40 mg received ATV, 300 mg, with RTV, 100 mg.

Reporting group title	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg
-----------------------	----------------------------------------------------------

#### Reporting group description:

Subjects weighing 5 to <10 kg received atazanavir (ATV), 150-mg powder dosed in 50-mg sachet packets, and ritonavir (RTV) oral solution, 80 mg. Stage 1: Initial dose was determined by subject's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). If water was used, mixture must have been taken with food. The entire contents of the mixture must have been consumed to obtain the full dose. The ritonavir oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Subjects who reached the age of 6 years or a weight of 25 kg were transitioned to the capsule formulation of ATV. Those who weighed 15 to <20 kg received ATV, 150 mg, with RTV, 100 mg; those who weighed 20 to <40 mg received ATV, 200, with RTV, 100 mg; and those who weighed at least 40 mg received ATV, 300 mg, with RTV, 100 mg.

Reporting group title	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg
-----------------------	----------------------------------------------------------

#### Reporting group description:

Subjects weighing 10 to <15 kg received ATV powder, 200 mg, dosed in 50-mg sachet packets and RTV oral solution, 80 mg. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). If water was used, mixture must have been taken with food. All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Subjects who reached the age of 6 years or a weight 25 kg were transitioned to the capsule formulation of ATV. Those who weighed 15 to <20 kg received ATV, 150 mg, with RTV, 100 mg; those who weighed 20 to <40 mg received ATV, 200, with RTV, 100 mg; and those who weighed at least 40 mg received ATV, 300 mg, with RTV, 100 mg.

Reporting group title	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg
-----------------------	----------------------------------------------------------

Reporting group description:

Subjects weighing 15 to <25 kg received 250 mg of ATV powder dosed in 50-mg sachet packets, with 80 mg of RTV solution. Stage 1: Initial dose was determined by the subject's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). If water was used, mixture must have been taken with food. The entire contents of the mixture must have been consumed to obtain the full dose. The ritonavir oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Subjects who reached the age of 6 years or a weight 25 kg were transitioned to the capsule formulation of ATV. Those who weighed 15 to <20 kg received ATV, 150 mg, with RTV, 100 mg; those who weighed 20 to <40 mg received ATV, 200, with RTV, 100 mg; and those who weighed at least 40 mg received ATV, 300 mg, with RTV, 100 mg.

Subject analysis set title	ARV-experienced
----------------------------	-----------------

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

Antiretroviral (ARV) treatment-experienced subjects were those with previous exposure to ARV drugs through prior treatment for HIV infection or through postnatal treatment with  $\geq 1$  ARVs for the prevention of mother-to-child-transmission in accordance with multiple international guidelines.

Subject analysis set title	ARV-naive
----------------------------	-----------

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

ARV treatment-naive subjects were those with no prior exposure to ARV treatment. Subjects exposed to ARVs in utero or intrapartum were also considered treatment naive.

### Primary: Number of Subjects With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation

End point title	Number of Subjects With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation <sup>[1]</sup>
-----------------	-----------------------------------------------------------------------------------------------------------------------------------------

End point description:

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 to Week 48

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics were planned for this outcome measure.

End point values	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	19	16	
Units: Subjects				
Deaths	0	0	0	
SAEs	5	2	4	
AEs leading to discontinuation	4	1	0	

### Statistical analyses

No statistical analyses for this end point

**Primary: Number of Subjects With Laboratory Test Results With Worst Toxicity of Grade 3-4**

End point title	Number of Subjects With Laboratory Test Results With Worst Toxicity of Grade 3-4 <sup>[2]</sup>
-----------------	-------------------------------------------------------------------------------------------------

End point description:

ALT=alanine aminotransferase; SGPT=serum glutamic-pyruvic transaminase; AST=aspartate aminotransferase; SGOT=serum glutamic-oxaloacetic transaminase; ULN=upper limit of normal. Grading by the National Institute of Health Division of AIDS and World Health Organization criteria. Hemoglobin (g/dL): Grade (Gr)1=9.5-11.0; Gr 2=8.0-9.4; Gr 3=6.5-7.9; Gr 4=<6.5. Neutrophils, absolute (/mm<sup>3</sup>): Gr 1=>=1000-<1500; Gr 2= >=750-<1000; Gr 3=>=500-<750; Gr 4=<500. ALT/SGPT (\*ULN): Gr 1=1.25-2.5; Gr 2=2.6-5; Gr 3=5.1-10; Gr 4=>10. AST/SGOT (\*ULN): Gr 1=1.25-2.5; Gr 2=2.6-5; Gr 3=5.1-10; Gr 4=>10. Alkaline phosphatase(\*ULN): Gr 1=1.25-2.5; Gr 2=2.6-5; Gr 3=5.1-10; Gr 4=>10. Total bilirubin (\*ULN): Gr 1=1.1-1; Gr 2=1.6-2.5; Gr 3=2.6-5; Gr 4=>5. Amylase (\*ULN): Gr 1=1.10-39; Gr 2=1.40-2; Gr 3=2.10-5.0; Gr 4=>5.0. Lipase (\*ULN): Gr 1=1.10-1.39; Gr 2=1.40-2; Gr 3=2.10-5.0; Gr 4=>5.0. Uric acid (mg/dL): Gr 1=7.5-10.0; Gr 2=10.1-12.0; Gr 3=12.1-15.0; Gr 4=>15.

End point type	Primary
----------------	---------

End point timeframe:

After Day 1 to Week 48

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics were planned for this outcome measure.

End point values	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	19	16	
Units: Subjects				
Hemoglobin (n=20, 17, 15)	2	3	0	
Neutrophils, absolute (n=20, 17, 15)	3	2	0	
ALT/SGPT (n=20, 18, 15)	5	0	1	
AST/SGOT (n=20, 18, 15)	1	0	0	
Alkaline phosphatase (n=20, 18, 15)	0	1	0	
Total bilirubin (n=20, 18, 15)	2	0	3	
Amylase (n=20, 18, 15)	8	5	1	
Lipase (n=20, 18, 15)	0	1	1	
Uric acid n=20, 18, 15)	0	0	1	

**Statistical analyses**

No statistical analyses for this end point

**Primary: Electrocardiogram Changes From Baseline in PR Interval, QTc Bazett (QTcB), and QTc Fridericia (QTcF) at Week 48**

End point title	Electrocardiogram Changes From Baseline in PR Interval, QTc Bazett (QTcB), and QTc Fridericia (QTcF) at Week 48 <sup>[3]</sup>
-----------------	--------------------------------------------------------------------------------------------------------------------------------

End point description:

Electrocardiogram parameters were measured at baseline for QTcB, QTcF, and PR interval. The mean

change from baseline at week 48 is reported by arm in milliseconds.

End point type	Primary
----------------	---------

End point timeframe:

From Baseline to Week 48

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics were planned for this outcome measure.

End point values	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	15	13	
Units: Milliseconds				
arithmetic mean (standard deviation)				
PR Interval	4.9 (± 21.80)	12.0 (± 8.04)	6.2 (± 8.54)	
QTC Bazett	1.7 (± 17.73)	-3.2 (± 21.78)	-4.2 (± 13.02)	
QTC Fridericia	7.9 (± 18.36)	13.2 (± 18.92)	4.8 (± 11.49)	

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Subjects With Centers for Disease Control (CDC) Class C AIDS Events

End point title	Number of Subjects With Centers for Disease Control (CDC) Class C AIDS Events <sup>[4]</sup>
-----------------	----------------------------------------------------------------------------------------------

End point description:

CDC Class C events are AIDS-defining events that include recurrent bacterial pneumonia ( $\geq 2$  episodes in 12 months); candidiasis of the bronchi, trachea, lungs, or esophagus; invasive cervical carcinoma; disseminated or extrapulmonary coccidioidomycosis; extrapulmonary cryptococcosis; chronic intestinal cryptosporidiosis ( $> 1$  month); cytomegalovirus disease; HIV-related encephalopathy; herpes simplex: chronic ulcers, or bronchitis, pneumonitis, or esophagitis; disseminated or extrapulmonary histoplasmosis; chronic intestinal isosporiasis; Kaposi sarcoma; immunoblastic or primary brain Burkitt lymphoma; mycobacterium avium complex, kansasii, or tuberculosis; mycobacterium, other species; Pneumocystis carinii pneumonia; progressive multifocal leukoencephalopathy; Salmonella septicemia; recurrent toxoplasmosis of brain; HIV wasting syndrome (involuntary weight loss  $> 10\%$  of baseline body weight) with chronic diarrhea or chronic weakness and documented fever for  $\geq 1$  month.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 to Week 48

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics were planned for this outcome measure.

<b>End point values</b>	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	19	16	
Units: Subjects	1	1	0	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects With HIV RNA Levels <50 c/mL and <400 c/mL at Week 48 by Treatment/Weight

End point title	Percentage of Subjects With HIV RNA Levels <50 c/mL and <400 c/mL at Week 48 by Treatment/Weight
End point description:	The definition of virologic success included HIV RNA levels <50 c/mL or 400 c/mL at the Week 48 analysis window.
End point type	Secondary
End point timeframe:	At Week 48

<b>End point values</b>	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	19	14	
Units: Percentage of subjects				
number (not applicable)				
HIV RNA levels <50 c/mL	47.6	68.4	71.4	
HIV RNA levels <400 c/mL	66.7	73.7	85.7	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects With HIV RNA Levels <50 c/mL and <400 c/mL at Week 48 by Prior Antiretroviral (ARV) Treatment Status

End point title	Percentage of Subjects With HIV RNA Levels <50 c/mL and <400 c/mL at Week 48 by Prior Antiretroviral (ARV) Treatment Status
End point description:	The definition of virologic success included HIV RNA levels <50 c/mL or <400 c/mL at the Week 48 analysis.

End point type	Secondary
End point timeframe:	
From Day 1 to Week 48	

End point values	ARV-experienced	ARV-naive		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	34	22		
Units: Percentage of subjects				
number (not applicable)				
HIV RNA levels <50 c/mL	56.3	68.2		
HIV RNA levels <400 c/mL	65.6	86.4		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Mean Change From Baseline in HIV RNA Levels at Week 48 by Treatment/Weight

End point title	Mean Change From Baseline in HIV RNA Levels at Week 48 by Treatment/Weight
End point description:	
Subjects who received at least 1 dose of atazanavir (ATV) and had an HIV RNA measurement on ATV powder at did not switch to the capsule formulation before Week 48	
End point type	Secondary
End point timeframe:	
From Baseline to Week 48	

End point values	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	15	13	
Units: Log10 c/mL				
arithmetic mean (standard error)	-2.61 (± 0.3111)	-2.93 (± 0.1678)	-2.40 (± 0.2412)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Mean Change from Baseline in HIV RNA Levels at Week 48 by Prior

## Antiretroviral (ARV) Treatment Status

End point title	Mean Change from Baseline in HIV RNA Levels at Week 48 by Prior Antiretroviral (ARV) Treatment Status
-----------------	-------------------------------------------------------------------------------------------------------

End point description:

The mean change from baseline in HIV RNA levels was reported by arm at week 48 for all treated subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline to Week 48

End point values	ARV-experienced	ARV-naive		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	34	22		
Units: Log10 c/mL				
arithmetic mean (standard error)	-2.53 ( $\pm$ 0.2452)	-2.81 ( $\pm$ 0.1296)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: CD4 Cell Count Changes From Baseline at Week 48 by Treatment/Weight

End point title	CD4 Cell Count Changes From Baseline at Week 48 by Treatment/Weight
-----------------	---------------------------------------------------------------------

End point description:

The mean change from baseline in CD4 cell count at week 48 was reported by treatment/weight for all treated subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline to Week 48

End point values	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	11	5	
Units: Cells/mm <sup>3</sup>				
arithmetic mean (standard error)	550.1 ( $\pm$ 285.24)	225.3 ( $\pm$ 198.34)	373.8 ( $\pm$ 68.83)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: CD4 Cell Count Changes From Baseline at week 48 by Prior Antiretroviral (ARV) Treatment Status

End point title	CD4 Cell Count Changes From Baseline at week 48 by Prior Antiretroviral (ARV) Treatment Status
-----------------	------------------------------------------------------------------------------------------------

End point description:

The mean change from baseline in CD4 cell count at week 48 was reported for prior ARV treatment status.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline to Week 48

End point values	ARV-experienced	ARV-naive		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	34	22		
Units: Cells/mm <sup>3</sup>				
arithmetic mean (standard error)	437.9 (± 253.123)	352.1 (± 152.600)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Mean Percent Change of CD4% From Baseline at Week 48 by Treatment/Weight

End point title	Mean Percent Change of CD4% From Baseline at Week 48 by Treatment/Weight
-----------------	--------------------------------------------------------------------------

End point description:

The mean percent of change from baseline in CD4% is reported by arm for all treated subjects at week 48.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline to Week 48

End point values	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	14	12	6	
Units: Percentage of lymphocytes				
arithmetic mean (standard error)	6.1 (± 1.56)	7.3 (± 2.26)	8.8 (± 1.14)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Mean CD4 Percent Changes From Baseline at Week 48 by Antiretroviral (ARV) Treatment Status

End point title	Mean CD4 Percent Changes From Baseline at Week 48 by Antiretroviral (ARV) Treatment Status
-----------------	--------------------------------------------------------------------------------------------

End point description:

The mean change from baseline in CD4 % at week 48 was reported by prior ARV treatment status.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline to Week 48

End point values	ARV-experienced	ARV-naive		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	34	22		
Units: Percentage of lymphocytes				
arithmetic mean (standard error)	4.3 ( $\pm$ 1.316)	9.8 ( $\pm$ 1.496)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects Who Acquired Phenotypic Resistance to Atazanavir or Atazanavir/Ritonavir

End point title	Number of Subjects Who Acquired Phenotypic Resistance to Atazanavir or Atazanavir/Ritonavir
-----------------	---------------------------------------------------------------------------------------------

End point description:

Criteria for resistance testing= meeting at least 1 of the following: <1 log<sub>10</sub> drop from baseline in HIV RNA level by Week 16 and confirmed by a second HIV RNA level; an HIV RNA level >200 copies/mL after Week 24, confirmed by a second HIV RNA level; repeated HIV RNA levels  $\geq$ 50 copies/mL after Week 48; an HIV RNA level  $\geq$ 400 copies/mL confirmed by a second HIV RNA level of  $\geq$ 400 copies/mL at any time in a subject who had previously achieved a plasma HIV RNA level <50 copies/mL; or discontinued due to lack of efficacy. Virologic failure was defined as an incomplete virologic response to therapy or as a viral rebound after the achievement of virologic suppression. The phenotypic resistance to a drug is defined as a fold change (ie, ratio of the 50% inhibitory concentration [IC<sub>50</sub>] of the clinical isolate to the IC<sub>50</sub> of the reference strain) greater than the cut-off for reduced susceptibility.

End point type	Secondary
----------------	-----------

End point timeframe:

After Day 1 to through Week 48

<b>End point values</b>	ARV-experienced	ARV-naive		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	6	8		
Units: Subjects				
Atazanavir	0	0		
Ritonavir	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of Atazanavir and Ritonavir

End point title	Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of Atazanavir and Ritonavir
-----------------	-------------------------------------------------------------------------------------------------------------

End point description:

Serial plasma concentrations will be collected over a 24-hour period at Week 2 in order to assess the steady state PK of ATV and RTV. Pharmacokinetic parameters of ATV and RTV will be derived from plasma concentration versus time data by a non-compartmental method using a validated pharmacokinetic program.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 2 at Hour 0 predose and at Hours 1.5, 2.5, 4, 6, 8, 12, and 24 postdose

<b>End point values</b>	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	20	18	15	
Units: ng/mL				
geometric mean (full range (min-max))				
Atazanavir Cmax	4131 (1110 to 9660)	5197 (390 to 15000)	6172 (3560 to 10400)	
Atazanavir Cmin	336 (11.4 to 1330)	572 (11.2 to 4870)	698 (238 to 2410)	
Ritonavir Cmax (n=19, 18, 15)	2919 (188 to 9160)	2634 (163 to 17700)	1838 (582 to 4960)	
Ritonavir Cmin (n=18, 16, 15)	41.8 (12.7 to 311)	143 (14.2 to 1610)	51.0 (9.0 to 468)	

## Statistical analyses

No statistical analyses for this end point

---

**Secondary: Area Under the Concentration Curve (in 1 Dosing Interval From Time 0 to 24 Hours Post Observed Dose) (AUC[TAU])of Atazanavir and Ritonavir**

---

End point title	Area Under the Concentration Curve (in 1 Dosing Interval From Time 0 to 24 Hours Post Observed Dose) (AUC[TAU])of Atazanavir and Ritonavir
-----------------	--------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Serial plasma concentrations will be collected over a 24-hour period at Week 2 in order to assess the steady state PK of ATV and RTV. Pharmacokinetic parameters of ATV and RTV will be derived from plasma concentration versus time data by a non-compartmental method using a validated pharmacokinetic program.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 2 at Hour 0 predose and at Hours 1.5, 2.5, 4, 6, 8, 12, and 24 postdose

---

End point values	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	20	18	15	
Units: ng*h/mL				
geometric mean (full range (min-max))				
AUC(TAU) Atazanavir	32503 (10441 to 94352)	50305 (6697 to 189971)	61485 (31599 to 117171)	
AUC(TAU) Ritonavir (n=19, 18, 15)	17439 (1322 to 56864)	20510 (971 to 229777)	13640 (3376 to 40806)	

---

**Statistical analyses**

---

No statistical analyses for this end point

---

---

**Secondary: Time to Maximum Observed Concentration (Tmax) of Atazanavir and Ritonavir**

---

End point title	Time to Maximum Observed Concentration (Tmax) of Atazanavir and Ritonavir
-----------------	---------------------------------------------------------------------------

End point description:

Serial plasma concentrations will be collected over a 24-hour period at Week 2 in order to assess the steady state PK of ATV and RTV. Pharmacokinetic parameters of ATV and RTV will be derived from plasma concentration versus time data by a non-compartmental method using a validated pharmacokinetic program.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 2 at Hour 0 predose and at Hours 1.5, 2.5, 4, 6, 8, 12, and 24 postdose

---

<b>End point values</b>	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	20	18	15	
Units: Hours				
median (full range (min-max))				
Tmax Atazanavir	1.58 (1.40 to 12.0)	1.97 (1.00 to 6.00)	4.0 (1.5 to 6.0)	
Tmax Ritonavir (n=19, 18, 50)	1.8 (1.3 to 11.9)	2.9 (1.0 to 8.0)	4.0 (1.5 to 6.0)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Apparent Total Body Clearance (CLT/F) of Atazanavir and Ritonavir

End point title	Apparent Total Body Clearance (CLT/F) of Atazanavir and Ritonavir
-----------------	-------------------------------------------------------------------

End point description:

Calculated as dose divided by AUC(TAU). AUC(TAU)=area under the concentration-time curve in 1 dosing interval from time 0 to 24 hours post observed dose.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 2

<b>End point values</b>	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	20	18	15	
Units: L/h				
geometric mean (full range (min-max))				
CLT/F Atazanavir	4.61 (1.6 to 14.4)	3.98 (1.1 to 29.9)	4.07 (2.1 to 7.9)	
CLT/F Ritonavir (n=19, 18, 15)	4.59 (1.4 to 60.5)	3.90 (0.3 to 82.4)	5.87 (2.0 to 23.7)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Apparent Total Body Clearance per Body Weight (CLT/F) per Kilogram of Atazanavir and Ritonavir

End point title	Apparent Total Body Clearance per Body Weight (CLT/F) per Kilogram of Atazanavir and Ritonavir
End point description:	Calculated as CLT/F divided by body weight
End point type	Secondary
End point timeframe:	At Week 2

<b>End point values</b>	Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg	Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	20	18	15	
Units: L/h per kilogram				
geometric mean (full range (min-max))				
CLT/F per kilogram Atazanavir	0.65 (0.2 to 1.8)	0.32 (0.1 to 2.6)	0.24 (0.1 to 0.5)	
CLT/F per kilogram Ritonavir (n=19, 18, 15)	0.65 (0.2 to 7.5)	0.32 (0.04 to 5.9)	0.35 (0.1 to 1.4)	

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Events were reported from start of treatment up to 30 days following discontinuation of treatment (ATV powder or capsule, through Stages 1 and 2 combined).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	20.0

### Reporting groups

Reporting group title	Body Weight 5 Kilogram (kg) to less than 10 kg
-----------------------	------------------------------------------------

Reporting group description:

Subjects received 150 milligram (mg) Atazanvir (ATV) as powder (Initially contained 10 percent (%) aspartame, after protocol amendment quantity of aspartame reduced to 4.2%) and 100 mg Ritonavir (RTV) as oral solution once a day in combination of an optimized nucleoside backbone therapy. When participant reached to 6 years of age or had a body weight at least 25 Kilogram (kg) they transitioned to the capsule formulations of ATV and RTV.

Reporting group title	Body Weight 10 kg to less than 15 kg
-----------------------	--------------------------------------

Reporting group description:

Subjects received 200 mg ATV as powder (Initially contained 10% aspartame, after protocol amendment quantity of aspartame reduced to 4.2%) with 80 mg RTV as oral solution once a day in combination of an optimized nucleoside backbone therapy. When participant reached to 6 years of age or had a body weight at least 25 kg they transitioned to the capsule formulations of ATV and RTV.

Reporting group title	Body Weight 15 kg to less than 25 kg
-----------------------	--------------------------------------

Reporting group description:

Subjects received 250 mg ATV as powder (Initially contained 10% aspartame, after protocol amendment quantity of aspartame reduced to 4.2%) with 80 mg RTV as oral solution once a day in combination of an optimized nucleoside backbone therapy. When participant reached to 6 years of age or had a body weight at least 25 kg they transitioned to the capsule formulations of ATV.

<b>Serious adverse events</b>	Body Weight 5 Kilogram (kg) to less than 10 kg	Body Weight 10 kg to less than 15 kg	Body Weight 15 kg to less than 25 kg
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 21 (33.33%)	5 / 19 (26.32%)	6 / 16 (37.50%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Investigations			
Electrocardiogram qt prolonged			
subjects affected / exposed	0 / 21 (0.00%)	1 / 19 (5.26%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased			

subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Injury, poisoning and procedural complications</b>			
Humerus fracture			
subjects affected / exposed	0 / 21 (0.00%)	1 / 19 (5.26%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nervous system disorders</b>			
Febrile convulsion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	1 / 21 (4.76%)	0 / 19 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
Neutropenia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hepatobiliary disorders</b>			
Drug-Induced liver injury			
subjects affected / exposed	0 / 21 (0.00%)	1 / 19 (5.26%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory, thoracic and mediastinal disorders</b>			
Bronchiectasis			

subjects affected / exposed	0 / 21 (0.00%)	1 / 19 (5.26%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Psychiatric disorders</b>			
Suicide attempt			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Dengue fever			
subjects affected / exposed	0 / 21 (0.00%)	1 / 19 (5.26%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 19 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster disseminated			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	1 / 21 (4.76%)	0 / 19 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis bacterial			
subjects affected / exposed	1 / 21 (4.76%)	0 / 19 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media chronic			

subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumonia</b>			
subjects affected / exposed	2 / 21 (9.52%)	0 / 19 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Sepsis</b>			
subjects affected / exposed	1 / 21 (4.76%)	0 / 19 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Varicella zoster virus infection</b>			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Body Weight 5 Kilogram (kg) to less than 10 kg	Body Weight 10 kg to less than 15 kg	Body Weight 15 kg to less than 25 kg
<b>Total subjects affected by non-serious adverse events</b>			
subjects affected / exposed	21 / 21 (100.00%)	18 / 19 (94.74%)	15 / 16 (93.75%)
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>			
<b>Skin papilloma</b>			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	2 / 16 (12.50%)
occurrences (all)	0	0	3
<b>Vascular disorders</b>			
<b>Haematoma</b>			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	2
<b>General disorders and administration site conditions</b>			
<b>Asthenia</b>			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	2 / 16 (12.50%)
occurrences (all)	0	0	2
<b>Local swelling</b>			

subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	3 / 21 (14.29%) 3	7 / 19 (36.84%) 7	5 / 16 (31.25%) 6
Social circumstances Physical assault subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Respiratory, thoracic and mediastinal disorders Asthma subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	1 / 19 (5.26%) 3	1 / 16 (6.25%) 2
Bronchospasm subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	7 / 21 (33.33%) 13	6 / 19 (31.58%) 19	7 / 16 (43.75%) 21
Epistaxis subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	1 / 16 (6.25%) 1
Lung disorder subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	4 / 21 (19.05%) 4	3 / 19 (15.79%) 4	0 / 16 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Productive cough subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Rhinitis allergic			

subjects affected / exposed occurrences (all)	4 / 21 (19.05%) 6	3 / 19 (15.79%) 5	1 / 16 (6.25%) 4
Rhinorrhoea subjects affected / exposed occurrences (all)	5 / 21 (23.81%) 5	2 / 19 (10.53%) 3	1 / 16 (6.25%) 3
Sneezing subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	1 / 16 (6.25%) 1
Psychiatric disorders Enuresis subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Amylase increased subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Blood bilirubin increased subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 19 (0.00%) 0	1 / 16 (6.25%) 2
Blood sodium increased subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Body temperature increased subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Cardiac murmur subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Crystal urine present subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	1 / 16 (6.25%) 1
Electrocardiogram abnormal			

subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Lipase increased subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Urinary sediment present subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	4 / 21 (19.05%) 5	3 / 19 (15.79%) 3	1 / 16 (6.25%) 1
Injury, poisoning and procedural complications			
Animal bite subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Arthropod bite subjects affected / exposed occurrences (all)	5 / 21 (23.81%) 10	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Burns first degree subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Contusion subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Foreign body subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Limb injury subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Overdose subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Scar			

subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	2 / 19 (10.53%) 2	1 / 16 (6.25%) 1
Skin abrasion subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	1 / 16 (6.25%) 1
Upper limb fracture subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Cardiac disorders Atrioventricular block first degree subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Headache subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	3 / 16 (18.75%) 6
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	2 / 19 (10.53%) 4	0 / 16 (0.00%) 0
Basophilia subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	1 / 19 (5.26%) 2	1 / 16 (6.25%) 2
Basophilopenia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Eosinophilia subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	2 / 19 (10.53%) 2	2 / 16 (12.50%) 2
Leukopenia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 2	1 / 16 (6.25%) 1
Lymphadenitis			

subjects affected / exposed	2 / 21 (9.52%)	0 / 19 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Lymphadenopathy			
subjects affected / exposed	4 / 21 (19.05%)	4 / 19 (21.05%)	0 / 16 (0.00%)
occurrences (all)	5	4	0
Lymphocytosis			
subjects affected / exposed	1 / 21 (4.76%)	1 / 19 (5.26%)	1 / 16 (6.25%)
occurrences (all)	2	2	4
Lymphopenia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 19 (5.26%)	1 / 16 (6.25%)
occurrences (all)	0	1	1
Monocytopenia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 19 (5.26%)	1 / 16 (6.25%)
occurrences (all)	0	1	2
Monocytosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Neutropenia			
subjects affected / exposed	1 / 21 (4.76%)	1 / 19 (5.26%)	1 / 16 (6.25%)
occurrences (all)	2	3	1
Splenomegaly			
subjects affected / exposed	0 / 21 (0.00%)	1 / 19 (5.26%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Cerumen impaction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	3 / 16 (18.75%)
occurrences (all)	0	0	3
Ear pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 19 (5.26%)	3 / 16 (18.75%)
occurrences (all)	0	1	4
Excessive cerumen production			
subjects affected / exposed	1 / 21 (4.76%)	1 / 19 (5.26%)	0 / 16 (0.00%)
occurrences (all)	1	2	0
Otorrhoea			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	2 / 16 (12.50%)
occurrences (all)	0	0	2

Tympanic membrane perforation subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	1 / 19 (5.26%) 1	1 / 16 (6.25%) 1
Eye disorders			
Conjunctival hyperaemia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Conjunctivitis allergic subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Eye pruritus subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Gastrointestinal disorders			
Abdominal distension subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Abdominal pain subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	2 / 16 (12.50%) 3
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Anal pruritus subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Dental caries subjects affected / exposed occurrences (all)	4 / 21 (19.05%) 4	3 / 19 (15.79%) 5	3 / 16 (18.75%) 5
Diarrhoea subjects affected / exposed occurrences (all)	11 / 21 (52.38%) 22	6 / 19 (31.58%) 9	7 / 16 (43.75%) 7
Gastritis subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Oral mucosal blistering			

subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Tongue geographic subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	2 / 19 (10.53%) 2	2 / 16 (12.50%) 2
Vomiting subjects affected / exposed occurrences (all)	9 / 21 (42.86%) 13	8 / 19 (42.11%) 18	4 / 16 (25.00%) 8
<b>Hepatobiliary disorders</b>			
Hepatomegaly subjects affected / exposed occurrences (all)	4 / 21 (19.05%) 4	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 3	2 / 19 (10.53%) 4	4 / 16 (25.00%) 7
Jaundice subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	3 / 19 (15.79%) 5	2 / 16 (12.50%) 2
Ocular icterus subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2	1 / 19 (5.26%) 3	1 / 16 (6.25%) 2
<b>Skin and subcutaneous tissue disorders</b>			
Dandruff subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Dermatitis subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2	1 / 19 (5.26%) 1	1 / 16 (6.25%) 1
Dermatitis allergic subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Dermatitis diaper			

subjects affected / exposed	6 / 21 (28.57%)	1 / 19 (5.26%)	0 / 16 (0.00%)
occurrences (all)	7	2	0
Dry skin			
subjects affected / exposed	1 / 21 (4.76%)	1 / 19 (5.26%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Ecchymosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Eczema			
subjects affected / exposed	7 / 21 (33.33%)	4 / 19 (21.05%)	1 / 16 (6.25%)
occurrences (all)	8	5	3
Lipodystrophy acquired			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Macule			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Onychomadesis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Pityriasis alba			
subjects affected / exposed	2 / 21 (9.52%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	2	0	1
Prurigo			
subjects affected / exposed	0 / 21 (0.00%)	1 / 19 (5.26%)	1 / 16 (6.25%)
occurrences (all)	0	2	2
Pruritus			
subjects affected / exposed	0 / 21 (0.00%)	1 / 19 (5.26%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Rash			
subjects affected / exposed	2 / 21 (9.52%)	2 / 19 (10.53%)	2 / 16 (12.50%)
occurrences (all)	2	3	3
Rash papular			
subjects affected / exposed	2 / 21 (9.52%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	2	0	1
Seborrhoeic dermatitis			

subjects affected / exposed occurrences (all)	3 / 21 (14.29%) 4	0 / 19 (0.00%) 0	0 / 16 (0.00%) 0
Skin hyperpigmentation subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Skin lesion subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Skin ulcer subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Urticaria papular subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2	0 / 19 (0.00%) 0	0 / 16 (0.00%) 0
Renal and urinary disorders			
Dysuria subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
Leukocyturia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 2
Proteinuria subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 2
Back pain subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 2	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Joint swelling subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
Tendonitis			

subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
<b>Infections and infestations</b>			
<b>Acarodermatitis</b>			
subjects affected / exposed occurrences (all)	6 / 21 (28.57%) 10	0 / 19 (0.00%) 0	1 / 16 (6.25%) 2
<b>Bacteriuria</b>			
subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	1 / 19 (5.26%) 3	1 / 16 (6.25%) 1
<b>Bronchitis</b>			
subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2	4 / 19 (21.05%) 10	2 / 16 (12.50%) 6
<b>Candida nappy rash</b>			
subjects affected / exposed occurrences (all)	5 / 21 (23.81%) 9	0 / 19 (0.00%) 0	0 / 16 (0.00%) 0
<b>Conjunctivitis</b>			
subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2	2 / 19 (10.53%) 2	1 / 16 (6.25%) 1
<b>Ear infection</b>			
subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 6	1 / 19 (5.26%) 2	0 / 16 (0.00%) 0
<b>Enterobiasis</b>			
subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
<b>Folliculitis</b>			
subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	0 / 19 (0.00%) 0	1 / 16 (6.25%) 1
<b>Fungal infection</b>			
subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
<b>Fungal skin infection</b>			
subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2	1 / 19 (5.26%) 1	0 / 16 (0.00%) 0
<b>Gastroenteritis</b>			
subjects affected / exposed occurrences (all)	9 / 21 (42.86%) 18	5 / 19 (26.32%) 6	2 / 16 (12.50%) 2

Helminthic infection			
subjects affected / exposed	5 / 21 (23.81%)	2 / 19 (10.53%)	1 / 16 (6.25%)
occurrences (all)	8	2	1
Herpes simplex			
subjects affected / exposed	0 / 21 (0.00%)	1 / 19 (5.26%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Hordeolum			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Impetigo			
subjects affected / exposed	4 / 21 (19.05%)	2 / 19 (10.53%)	2 / 16 (12.50%)
occurrences (all)	7	3	3
Influenza			
subjects affected / exposed	3 / 21 (14.29%)	1 / 19 (5.26%)	2 / 16 (12.50%)
occurrences (all)	3	1	2
Lice infestation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Lower respiratory tract infection			
subjects affected / exposed	2 / 21 (9.52%)	3 / 19 (15.79%)	1 / 16 (6.25%)
occurrences (all)	3	7	1
Lower respiratory tract infection viral			
subjects affected / exposed	0 / 21 (0.00%)	1 / 19 (5.26%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Molluscum contagiosum			
subjects affected / exposed	0 / 21 (0.00%)	1 / 19 (5.26%)	1 / 16 (6.25%)
occurrences (all)	0	1	1
Nasopharyngitis			
subjects affected / exposed	3 / 21 (14.29%)	1 / 19 (5.26%)	5 / 16 (31.25%)
occurrences (all)	12	2	14
Oral candidiasis			
subjects affected / exposed	9 / 21 (42.86%)	0 / 19 (0.00%)	0 / 16 (0.00%)
occurrences (all)	10	0	0
Oral herpes			
subjects affected / exposed	0 / 21 (0.00%)	1 / 19 (5.26%)	2 / 16 (12.50%)
occurrences (all)	0	1	3

Otitis externa			
subjects affected / exposed	3 / 21 (14.29%)	3 / 19 (15.79%)	1 / 16 (6.25%)
occurrences (all)	3	3	1
Otitis media			
subjects affected / exposed	8 / 21 (38.10%)	4 / 19 (21.05%)	4 / 16 (25.00%)
occurrences (all)	17	9	10
Otitis media acute			
subjects affected / exposed	3 / 21 (14.29%)	2 / 19 (10.53%)	2 / 16 (12.50%)
occurrences (all)	4	4	2
Otitis media chronic			
subjects affected / exposed	3 / 21 (14.29%)	1 / 19 (5.26%)	2 / 16 (12.50%)
occurrences (all)	3	2	2
Parasitic gastroenteritis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Pharyngitis			
subjects affected / exposed	5 / 21 (23.81%)	4 / 19 (21.05%)	4 / 16 (25.00%)
occurrences (all)	6	4	4
Pharyngotonsillitis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 19 (0.00%)	2 / 16 (12.50%)
occurrences (all)	1	0	4
Pneumonia			
subjects affected / exposed	3 / 21 (14.29%)	2 / 19 (10.53%)	0 / 16 (0.00%)
occurrences (all)	3	2	0
Pulmonary tuberculosis			
subjects affected / exposed	2 / 21 (9.52%)	0 / 19 (0.00%)	0 / 16 (0.00%)
occurrences (all)	2	0	0
Respiratory tract infection			
subjects affected / exposed	1 / 21 (4.76%)	1 / 19 (5.26%)	2 / 16 (12.50%)
occurrences (all)	1	1	3
Rhinitis			
subjects affected / exposed	1 / 21 (4.76%)	1 / 19 (5.26%)	2 / 16 (12.50%)
occurrences (all)	1	1	3
Sinusitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	2 / 16 (12.50%)
occurrences (all)	0	0	3

Skin infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Tinea capitis			
subjects affected / exposed	4 / 21 (19.05%)	2 / 19 (10.53%)	2 / 16 (12.50%)
occurrences (all)	6	3	6
Tinea faciei			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Tinea infection			
subjects affected / exposed	1 / 21 (4.76%)	1 / 19 (5.26%)	3 / 16 (18.75%)
occurrences (all)	1	1	4
Tonsillitis			
subjects affected / exposed	7 / 21 (33.33%)	2 / 19 (10.53%)	1 / 16 (6.25%)
occurrences (all)	11	2	1
Tooth abscess			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	2
Upper respiratory tract infection			
subjects affected / exposed	11 / 21 (52.38%)	6 / 19 (31.58%)	5 / 16 (31.25%)
occurrences (all)	55	15	8
Urinary tract infection			
subjects affected / exposed	6 / 21 (28.57%)	2 / 19 (10.53%)	0 / 16 (0.00%)
occurrences (all)	8	2	0
Varicella			
subjects affected / exposed	2 / 21 (9.52%)	1 / 19 (5.26%)	1 / 16 (6.25%)
occurrences (all)	2	2	1
Viral rash			
subjects affected / exposed	1 / 21 (4.76%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	1	0	1
Viral upper respiratory tract infection			
subjects affected / exposed	4 / 21 (19.05%)	8 / 19 (42.11%)	4 / 16 (25.00%)
occurrences (all)	8	12	5
Vulvovaginal candidiasis			
subjects affected / exposed	1 / 21 (4.76%)	1 / 19 (5.26%)	0 / 16 (0.00%)
occurrences (all)	1	3	0

Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	5 / 21 (23.81%)	3 / 19 (15.79%)	2 / 16 (12.50%)
occurrences (all)	7	4	5
Hyperamylasaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	3
Hypercholesterolaemia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	3	0	1
Hyperlipasaemia			
subjects affected / exposed	1 / 21 (4.76%)	1 / 19 (5.26%)	0 / 16 (0.00%)
occurrences (all)	2	1	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 19 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	5

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 July 2010	The primary purpose of this amendment is as follows: 1) To clarify subjects' age range at time of first treatment, which will be 3 months to 5 years and 6 months of age. This change is to allow subjects who are nearly 6 years of age to have a minimum of 24 weeks of treatment with the powder formulation. 2) Additional visits are included in Stage 2 of the study. Subjects who switch to the capsule formulation will have 2 additional visits after the day of the switch. The new visits will be added at Weeks 4 and 8 following Day 0 of Stage 2 (day of switch to capsule). There will be a visit at Week 12 and every 12 weeks thereafter (ie, every 3 months). A transition period of 8 weeks is allowed to enable subjects to switch from the powder to the capsule. Subjects who are not able to swallow the capsule by the Stage 2 Week 8 week visit will be discontinued from the study. 3) Supplementary trough PK (ATV/RTV only) testing will be added as part of the clinical evaluation of a subject, for whom an investigator has a clinical concern (eg: a subject who has virologic rebound or is failing to suppress at a rate expected by the investigator).
18 April 2011	The purpose of this amendment is to clarify the intent to allow the use of both brand and generic locally approved and available NRTIs by removing statements not intended to have been in the protocol.
24 October 2011	1) To allow switch of NRTIs during the study in case of confirmed viral rebound $\geq 400$ copies virologic rebound $\geq 400$ copies/mL and $< 10,000$ copies/mL associated with a genotypic and / or phenotypic resistance to one or more assigned NRTI study drugs without genotypic and/or phenotypic resistance (including reduced sensitivity) to ATV or due to treatment-limiting NRTI toxicity 2) To add section on identification and reporting of events occurring in study participants which meet protocol-defined criteria of Drug Induced Liver Injury (DILI). 3) To allow RTV tablets in stage 2 of the study 4) To define treatment experienced subjects in Section 1.1 and Section 3.3.1. 5) To clarify the definition and management of virologic rebound and failure (Section 4.5.2) and discontinuation of subjects from treatment (Section 3.5). 6) To clarify that the age limit should be achieved at the time of first treatment. 7) Table 4.1 Product description: Added ritonavir tablet product information and updated the RTV oral solution storage conditions.
27 April 2012	1) To change the whole treatment regimen, including ATV, in patients with confirmed virologic failure or virologic rebound above 1000 copies/mL based on the resistance profile at failure in accordance with the recommendations from guidelines as per FDA comments on amendment 05 in Section 1.1. 2) Table 3.1.1B: Removed table note b as it is inconsistent with other protocol sections. Clarified in table title that ritonavir tablets or capsules should be used for pediatric patients (8 to less than 18 years of age). 3) To modify the definition of virologic failure in accordance with the updated 2011 DHHS pediatric guidelines in section 4.5.2 and clarify the virologic failure criteria to discontinue a subject in the study in Sections 3.5 and 4.5.2. 4) Table 4.1. Product description: Updated the ATV capsules storage conditions (excursions permitted 15-30°C) to be aligned with the

29 January 2013	<p>1) To switch all subjects in Stage 2, who are still on the current atazanavir oral powder formulation (10% aspartame), to the new 4.2% aspartame atazanavir oral powder formulation and to collect palatability/acceptability data at the time of switch and after the switch in Sections 3.1.1 and 4.1.</p> <p>2) Added background information on ATV 4.2% aspartame powder formulation in Section 1.4.</p> <p>3) Added that subject diaries should be used for subjects switching to the new 4.2% aspartame ATV powder formulation in stage 2 and as long as the subject is on the new ATV powder or maximum duration of one year, whichever comes first in Section 4.5.</p> <p>4) Added Adherence/Tolerability assessment procedures and added note that the assessments only apply to subjects remaining on ATV powder in Stage 2 in Time and Event Table 5.1C.</p> <p>5) Throughout the protocol, the numbering and lay-out of Tables and Figures is changed and hyperlinks are inserted.</p> <p>6) Cover page: BMS Research &amp; Development Belgium address has been changed</p>
15 April 2014	<p>1) To increase the blood volume collection from 1 up to 2 mL for HIV RNA testing in Stage 2 when switching to the new Abbott RealTime HIV-1 assay after the Roche Amplicor assay is discontinued.</p> <p>2) To address inconsistencies and administrative changes in Appendices 1 and 4.</p>

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported